Apostle Announces New Board Member And Advisors

Published: Jun 15, 2017

SUNNYVALE, Calif., June 15, 2017 /PRNewswire-iReach/ -- Apostle Inc is pleased to announce the appointment of William Dai, MBA as a new member to its Board of Directors, and Charles Cantor, PhD and Hongyu Zhao, PhD as new members to its Advisory Board.

"I'm pleased to welcome William, Charles, and Hongyu," said David Ge, CEO and Chairman of Apostle. "These individuals bring a wealth of experience and expertise in their fields and will add tremendous value to our company as we further our mission of bringing innovative technologies to help the general population with the early detection of cancer."

Biographical Notes

William Dai is Founding Partner of ShangBay Capital, a venture capital company located in the Silicon Valley. William has more than 20 years of experience in corporate finance, mergers and acquisitions, and capital markets in both China and the U.S. He has held senior executive roles at major U.S. multinational companies. In those roles, William was responsible for overall execution and was held accountable to the highest ethical standards in his business dealings.  He is well-respected among financial and investment circles, and is a recognized leader in the industry. In addition, due to his hands-on experience leading multiple large international medical device companies, he has a very in-depth knowledge of the medical device industry and its market dynamics.

William holds an MBA with an emphasis on finance from Michigan State University.  Prior to ShangBay Capital, he was appointed as CFO of ShangPharma Corporation (NYSE:SHP), one of the largest CROs in China; CFO of China Nepstar Corporation (NYSE: NPD), the largest chain drugstore in China; as wells as CFO and Vice Chair of the Executive Committee of Microport Scientific Corporation (HK: 00853), one of the largest medical device companies in China.  Previously, he was CFO of China at Boston Scientific Corporation (NYSE: BSX), one of the largest invasive medical device company in the world and Finance Manager at Treasury at Ford Motor Company in Michigan.

Charles Cantor is a member of the National Academy of Sciences.  He was Director of the U.S. national Human Genome Project (HGP), Chair of the Department of Biomedical Engineering and Biophysics, and Director of the Center for Advanced Biotechnology at Boston University. Prior to that time, Dr. Cantor held positions at Columbia University and the University of California, Berkeley.  A world-renowned scientist, he has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.

Charles is Professor Emeritus of Biomedical Engineering at Boston University and holds a Ph.D. in Biophysical Chemistry from University of California, Berkeley and an A.B. of Chemistry from Columbia University.  Charles is a molecular geneticist who, in conjunction with David Schwartz, developed pulse field gel electrophoresis for very large DNA molecules. His 3 vol book, Biophysical Chemistry, co-authored with Paul Schimmel, was an influential textbook in the 1980s and 1990s. Dr. Cantor was a founder and former Chief Scientific Officer of Sequenom, Inc. and is also the founder of Retrotope, Inc.

Hongyu Zhao is the Ira V. Hiscock Professor of Biostatistics and Professor of Statistics and Genetics, Chair of the Biostatistics Department and the Co-Director of Graduate Studies of the Inter-Departmental Program in Computational Biology and Bioinformatics at Yale University. He received his B.S. in probability and statistics from Peking University in 1990 and Ph.D. in statistics from the University of California at Berkeley in 1995. His research interests are the applications of statistical methods in molecular biology, genetics, drug developments, and personalized medicine. Prof. Zhao has published over 430 articles in statistics, human genetics, bioinformatics, and proteomics, and edited two books on human genetics analysis and statistical genomics. He has trained over 70 doctoral and post-doctoral students, many of whom are holding tenured or tenure-track positions at major universities in the United States and overseas.

Dr. Zhao is a Co-Editor-Elect of the Journal of the American Statistical Association Theory and Methods, and serves on the editorial boards of several leading statistical and genetics journals. He was the recipient of the Mortimer Spiegelman Award for a top statistician in health statistics under the age of 40 awarded by the American Public Health Association. His research has also been recognized by the Evelyn Fix Memorial Medal and Citation by UC Berkeley, a Basil O'Connor Starter Scholar Award by the March of Dimes Foundation, election to the fellowship of the American Association for the Advancement of Science, the American Statistical Association and the Institute of Mathematical Statistics.

About Apostle Inc

Apostle Inc is a biotechnology company in Sunnyvale, CA. It's in the business of the research, development, licensing, and sales of novel MiniMax magnetic nanoparticle technology, Triton cancer genome deep learning technology, AI-enabled nanoDiagnostics (AID) technology, and the related intellectual properties, products, and services for diagnosis and treatment of human diseases, to fundamentally improve the accuracy of cancer diagnosis at early stage.

More information can be found at www.apostlebio.com.

For media: pr@apostlebio.com

Media Contact: Dongliang Ge, Apostle, Inc, 650-483-5437, dge@apostlebio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Apostle, Inc

Back to news